Evidence map›Paper›PMID 37129215›Full record

ArticleJournal of diabetes science and technology2023

Evidence and Diabetes Technology: A Catch-22?

Norbert Hermanns, Bernd Kulzer, David C Klonoff, Lutz Heinemann

Abstract readEditorial
In one paragraph

Article in Journal of diabetes science and technology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Analysis of Adverse Events in Medical Devices for Diabetes.Journal of diabetes science and technology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Norbert HermannsResearch Institite of the Diabetes Acaemy Mergentheim (FIDAM), Bad Mergentheim, Germany.
Bernd KulzerResearch Institite of the Diabetes Acaemy Mergentheim (FIDAM), Bad Mergentheim, Germany.
David C KlonoffDiabetes Research Institute, Mills-Peninsula Medical Center, San Mateo, CA, USA.ORCID 0000-0001-6394-6862
Lutz HeinemannScience Consulting in Diabetes GmbH, Kaarst, Germany.ORCID 0000-0003-2493-1304

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetes technology is a dynamically evolving field. Sometimes the pace of evaluation of new diabetes technologies does not keep pace with its dynamic development. This leads to a dilemma: either the evaluation lags behind the developing technologies or diabetes technologies are used without sufficient evaluation. This situation is known as the Catch 22 dilemma. The aim of this paper is a discussion of ideas for a timely assessment, taking account of the speed of technological development and the need for evidence and safety improvement.

Indexed as

Diabetes MellitusDiabetes Mellitus, Type 1Blood GlucoseBlood Glucose Self-MonitoringHumansHypoglycemic AgentsInsulinTechnologyBlood GlucoseHypoglycemic AgentsInsulinCGM systemsdiabetes technologyevidenceglucose monitoringinsulin pens

Identifiers

PMID37129215
PMCPMC10658697

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.